Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 163,562 | 125,853 | 103,962 | 99,476 | 71,681 |
| Cost of Goods | 23,024 | 21,797 | 19,929 | 13,302 | 12,176 |
| Gross Profit | 140,538 | 104,056 | 84,033 | 86,174 | 59,505 |
| Operating Expenses | 334,784 | 330,052 | 283,821 | 296,634 | 357,754 |
| Operating Income | -194,222 | -225,199 | -198,859 | -210,158 | -298,073 |
| Interest Expense | 28,517 | 28,731 | 27,248 | 0 | 0 |
| Other Income | -20,860 | 1,478 | 48,204 | 28,512 | 21,490 |
| Pre-tax Income | -243,599 | -252,452 | -177,903 | -181,646 | -276,583 |
| Income Tax | -59 | 839 | 1,326 | 575 | -398 |
| Net Income Continuous | -243,540 | -253,291 | -179,229 | -182,221 | -276,185 |
| Net Income | $-243,540 | $-253,291 | $-179,229 | $-182,221 | $-276,185 |
| EPS Basic Total Ops | -2.10 | -2.18 | -1.56 | -1.62 | -2.44 |
| EPS Basic Continuous Ops | -2.10 | -2.18 | -1.56 | -1.62 | -2.44 |
| EPS Diluted Total Ops | -2.10 | -2.18 | -1.56 | -1.62 | -2.44 |
| EPS Diluted Continuous Ops | -2.10 | -2.18 | -1.56 | -1.62 | -2.44 |
| EBITDA(a) | $-173,342 | $-206,428 | $-181,081 | $-193,152 | $-283,311 |